Wai Chun Bio-Technology (HKG:0660) widened its attributable loss for the year ended June 30 to HK$44.2 million from HK$15.4 million in the year-ago period, a Dec. 20 filing on the Hong Kong bourse stated.
Loss per share was HK$0.258, up from HK$0.091 in the corresponding period of the last fiscal year.
The modified starch and other biochemical product company's revenue fell by 52% to HK$370.1 million in the fiscal year from HK$773.7 million a year prior.
The firm attributed the higher loss mainly to the recognition of impairment losses on non-financial assets in the fiscal year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。